UPDATE: Goldman Sachs Starts TG Therapeutics (TGTX) at Neutral

Goldman Sachs analyst Graig Suvannavejh initiates coverage on TG Therapeutics (NASDAQ: TGTX) with a Neutral rating and a price target of $50.00.

The analyst comments "TGTX is a US biopharmaceutical company, with a diversified pipeline that features two late-stage assets in umbralisib (already approved as Ukoniq for cancer) and ublituximab (an anti-CD20 antibody, with positive Phase 3 data already in hand in both cancer and multiple sclerosis/MS). While TGTX is also advancing an earlier stage oncology pipeline, our primary focus rests on (1) the commercial prospects for umbralisib and ublituximab, and (2) the ability of TGTX, on its own, to successfully execute on multiple commercial launches."

For an analyst ratings summary and ratings history on TG Therapeutics click here. For more ratings news on TG Therapeutics click here.

Shares of TG Therapeutics closed at $42.81 yesterday.

You May Also Be Interested In

• Benchmark Reiterates Buy Rating on CrowdStrike (CRWD) Following Record Q2
• Okta, Inc (OKTA) PT Raised to $200 at Truist Securities
• Nomura/Instinet Downgrades Vipshop Holdings (VIPS) to Neutral